<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495013</url>
  </required_header>
  <id_info>
    <org_study_id>115317</org_study_id>
    <nct_id>NCT01495013</nct_id>
  </id_info>
  <brief_title>A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Study ATG115317, a Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination
      tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate
      tablets, in improving glycaemic control (glycated haemoglobin, HbA1c) and cholesterol levels
      (Low-density lipoprotein, LDL) in diabetic subjects, who are inadequately controlled on a
      stable dose of metformin. Eight dose combinations will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with Type 2 diabetes (T2D) are initially provided with lifestyle advice in
      order to manage the condition by diet, exercise and weight reduction, followed by treatment
      with metformin. However, many patients do not gain adequate control of fasting glucose by
      these methods and other anti-diabetic agents are needed. Furthermore, these patients have an
      increased cardiovascular risk compared with the general population. Approximately one half of
      patients with T2D die prematurely of a cardiovascular cause and approximately 10% die of
      renal failure.

      Atherogenic dyslipidemia, which is defined as the triad of elevated triglycerides, low
      high-density lipoprotein cholesterol (HDL-C), and small low-density lipoprotein cholesterol
      (LDL-C) particles, is commonly found in individuals with T2D. In diabetic patients, the LDL
      particles tend to be smaller, denser, and more atherogenic than in the general population. As
      a result, in patients with diabetes, lowering LDL-C levels may lead to a greater benefit in
      terms of Cardiovascular disease (CVD) risk reduction than in patients without diabetes.
      Multiple clinical trials have demonstrated significant benefits of lipid-lowering (primarily
      statin) therapy on CVD outcomes for primary and secondary prevention, irrespective of
      baseline lipid levels. Hence, clinical treatment guidelines recommend that patients with T2D
      should be treated with both an anti-diabetic agent and a statin.

      Glimepiride is an established once-daily sulphonylurea for use as first-line therapy, and is
      often used in patients who are metformin intolerant, or in those who are failing to achieve
      glucose control on metformin monotherapy. Atorvastatin is an established statin that is
      indicated for reducing the risk of cardiovascular events in diabetic patients, without
      clinically evident coronary heart disease (CHD), irrespective of whether cholesterol is
      raised. The risk:benefit of both glimepiride and atorvastatin is well established and
      described in the approved product labels. There is widespread use of both glimepiride and
      atorvastatin, prescribed separately, in the T2D population. The available literature
      indicates that there is no drug-drug interaction risk associated with this combination
      therapy and no clinical PK interactions between atorvastatin and glimepiride have been
      recorded. A once-daily combination product which combines both glimepiride and atorvastatin
      will fulfil an unmet clinical need in simplifying patient treatment regimens in a patient
      population who have a significant disease burden. Providing concurrent access to a statin in
      patients with T2D, in addition to medication to manage glucose levels, is a critical
      requirement for ensuring appropriate management of cardio-metabolic risk.

      In this study, subjects already on a stable dose of metformin will be randomised to either to
      receive the glimepiride/atorvastatin fixed dose combination treatment or atorvastatin +
      glimepiride combination taken as separate tablets. The starting dose for all subjects will be
      1mg glimepiride and 10mg atorvastatin. The glimepiride dose will be titrated up if the
      average fasting glucose is &gt;7.0mmol/L. The atorvastatin dose will be titrated up if LDL is
      &gt;2.6mmol/L.

      The purpose of the study is to demonstrate non-inferiority of the glimepiride/atorvastatin
      fixed dose combination compared with glimepiride +atorvastatin taken as separate tablets in
      reducing HbA1c and LDL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing HbA1c levels</measure>
    <time_frame>Week 20</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing LDL levels</measure>
    <time_frame>Week 20</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">427</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg Glimepiride/10mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2mg Glimepiride/10mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3mg Glimepiride/10mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4mg Glimepiride/10mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg Glimepiride/20mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2mg Glimepiride/20mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3mg Glimepiride/20mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4mg Glimepiride/20mg Atorvastatin FDC</intervention_name>
    <description>1 tablet by mouth once a day</description>
    <arm_group_label>Glimepiride Atorvastatin fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg Glimepiride</intervention_name>
    <description>1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily</description>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2mg Glimepiride</intervention_name>
    <description>1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily</description>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3mg Glimepiride</intervention_name>
    <description>1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily</description>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4mg Glimepiride</intervention_name>
    <description>1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily</description>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10mg Atorvastatin</intervention_name>
    <description>1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily</description>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20mg Atorvastatin</intervention_name>
    <description>1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily</description>
    <arm_group_label>Glimepiride +Atrovastatin loose combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (≥18 years of age) males and females ( including of child-bearing potential)
             with Type 2 diabetes mellitus.

          -  Currently treated for Type 2 daibetes mellitus with metformin monotherapy and have
             been a stable dose of metformin for atleast 3 months

          -  patients with CVD or ≥40 years old with a cardiovascular risk factor, or &lt;40 years old
             with LDL-C level 100mg/dL

          -  HbA1c levels ≥7.0 and &lt;9.5% at screening or within 3 months prior to study enrollment

          -  Fasting blood glucose &gt;7.0 mmol/L on 4 days in a week

          -  Statin-naïve or no statin use for 2 months prior to screening

          -  Provision of informed consent

        Exclusion Criteria:

          -  Concomitant treatment:

          -  Concomitant treatment with statins other than study medication

          -  Concomitant treatment with fenofibrate or other lipid lowering agents

          -  concomitant treatment with anti-diabetic therapy other than study treatment or change
             in metformin monotherapy for subjects already treated with metformin

          -  Concurrent diseases and symptoms:

          -  Subjects with Type 1 diabetes or who have a current need for insulin therapy

          -  Subjects with symptomatic hyperglycaemia requiring immediate therapy in the judgement
             of the investigator

          -  Subjects with myalgia

          -  Significant hypertriglyceridaemia as defined by fasting triglycerides &gt;3.5 mmol/L

          -  Clinically significant ongoing cardiovascular disease:

          -  Subjects who have had an acute cardiovascular event within 30 days prior to
             randomisation

          -  Subjects with unstable or severe angina, coronary insufficiency or New York Heart
             Association class III-IV heart failure

          -  subjects with a prior heart transplant or who are awaiting a heart transplant

          -  Subjects with systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;90 mmHg
             while on anti-hypertensive treatment

          -  General Health:

          -  Subjects with end stage renal disease requiring renal replacement therapy

          -  Subjects receiving drug therapy to treat liver disease

          -  Subjects with diagnosis of cancer ( other than superficial squamous. basal cell skin
             cancer or adequately treated cervical carcinoma in situ) in the past 3 years or who
             are currently receiving treatment for an active cancer ( other than prophylactic)

          -  Subjects with a clinically significant abnormality identified at screening on physical
             examination or laboratory tests (including thyroid stimulating hormone) which, in the
             judgement of the investigator, would preclude safe completion of the study

          -  Subjects with anaemia defined by a haemoglobin concentration &lt;10 g/dL (100) g/L) for
             females and &lt;12 g/dL (120 g/L) for males or a haemoglobinopathy that could interfere
             with the assessment of HbA1c

          -  Subjects with clinically significant liver disease as defined by alanine
             aminotransferase ( ALT) or aspartate aminotransferase (AST) levels &gt;2.5 times the
             upper limit of normal (ULN) or a diagnosis of Chronic active hepatitis including that
             of viral aetiology, or on antiviral or immunosuppressive therapy

          -  Subjects with contraindications to or history of hypersensitivity to, the
             investigational products

          -  Subjects who are clinically or medically unstable, with expected survival &lt;1 year

          -  Subjects with a recent history ( within the last 6 months ) or suspicion of current
             drug abuse or alcohol abuse

          -  Any other factor likely to limit protocol compliance or reporting of adverse events

          -  Previous study participation:

          -  Participation in another clinical trial of an investigational agent, if the subject
             has used an investigational agent within 30 days or 5 half lives (whichever is longer)
             preceding the Screening Visit

          -  Previous randomisation in this study

        Contraception:

          -  Females of child-bearing potential who are not using highly effective methods for
             avoiding pregnancy. Highly effective methods include:

          -  Oral Contraceptive, either combined or progestogen alone

          -  Injectable progestogen

          -  Implants of levonorgestrel

          -  Estrogenic vaginal ring

          -  Percutaneous contraceptive patches

          -  Intrauterine device or intrauterine system with a failure rate of less than 1% per
             year

          -  Male partner sterilisation (vasectomy with documentation of azoospermia) prior to the
             female subject's entry into the study, and this male is the sole partner for that
             subject. For this definition, &quot;documented&quot; refers to the outcome of the
             investigator's/designee's medical examination of the subject or review of the
             subject's medical history for study eligibility, as obtained via a verbal interview
             with the subject or from the subject's medical records

          -  Double barrier method: condom and an occlusive cap(diaphragm or cervical/vault caps)
             with a vaginal spermicidal agent (foam/gel/film/cream/suppository), including
             nonoxynol-9
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon</city>
        <zip>134 727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangwondo</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seocho-ku, Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seongnam-si Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>139-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>463442</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ipoh</city>
        <zip>30450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johor Bahru</city>
        <zip>80100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kubang Kerian</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Del. Cuauhtémoc</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gadalajara, Jalisco</city>
        <zip>C.P. 44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara Jalisco</city>
        <zip>C.P. 44210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>11650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pasig City</city>
        <zip>1600</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sta. Cruz, Manila</city>
        <zip>1012</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiangrai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rajathevee</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <disposition_first_submitted>March 6, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 3, 2014</disposition_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-inferiority</keyword>
  <keyword>glimepiride</keyword>
  <keyword>LDL cholesterol</keyword>
  <keyword>fixed dose combination</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115317</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115317</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115317</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115317</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115317</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115317</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>August 24, 2017</submitted>
    <returned>March 21, 2018</returned>
    <submitted>April 24, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

